Video of Regeneron leaders reflecting on 2021 achievements.

For nearly 35 years, our mission has been to use the power of science to bring new medicines to patients. To achieve this, we seek to constantly improve the drug discovery and development process by applying our homegrown technologies, deep understanding of science and relentless spirit. Our physician-scientist leaders reflect on what we achieved together in 2021.

Regeneron by the numbers

(as of April 2022)

9out of10

employees say
Regeneron is a great
place to work

30+

investigational medicines in clinical development

146

global and U.S. patient advocacy and professional societies engaged across 28 diseases

clinical trials in

55+

COUNTRIES

Offices in

COUNTRIES

(U.S., Ireland, England, Canada, Germany and the Netherlands)

FDA-approved
medicines

12K+

HOURS

of Regeneron volunteer
service to local
communities during
fifth annual Day for
Doing Good

~2M

exomes sequenced
by the Regeneron
Genetics Center^®

670K

students who participated
in STEM programs
provided by Regeneron

40M+

DOSES

of EYLEA^® (aflibercept)
Injection administered
worldwide since launch
10+ years ago

2.8M

doses of REGEN-COV^®
(casirivimab and imdevimab)
delivered to U.S. government

active molecules managed by Industrial Operations and Product Supply

Responsibility
Report

As we create novel medicines for people in need, corporate responsibility is fundamental to everything we do. We are applying our unique science-led approach to advance our global 2025 responsibility goals and working to improve our world. Go deeper in our Responsibility Report 2021.

View the report

Proxy Statement and Notice of Annual Shareholder Meeting 2022.

READ OUR 2022 PROXY STATEMENT

This Year in Review contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Please see Regeneron’s press release announcing its financial and operating results for the quarter and year ended December 31, 2021 for important information about Regeneron’s forward-looking statements.